Background: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is efficacious in treating moderate-to-severe plaque psoriasis through 60 weeks.
Limitations: There was no comparison treatment group after week 12.
Conclusion: Ixekizumab is well tolerated and demonstrates persistent efficacy through 108 weeks. ( J Am Acad Dermatol 2017;77:855-62.)
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Accumulating evidence supports a central role of interleukin (IL) 17A in the pathogenesis of psoriasis and other autoimmune disorders. 1 Ixekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A. 2 In 3 randomized, controlled phase 3 clinical trials, ixekizumab was well tolerated and was efficacious in treating patients with moderate-tosevere plaque psoriasis through 12 and 60 weeks. 3, 4 Given the chronic nature of psoriasis, long-term safety and efficacy are pressing concerns for agents used in its treatment. The primary objective of this study was to report the long-term efficacy of ixekizumab up to 108 weeks of treatment in UNCOVER-3, with a focus on patients receiving the recommended dosing regimen (80 mg ixekizumab every 2 weeks up to week 12 and every 4 weeks thereafter). An overview of long-term safety outcomes is also presented.
METHODS

Study design and participants
UNCOVER-3 is a randomized, double-blind, multicenter, phase-3 clinical trial to evaluate the long-term efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis. The study design and patient selection criteria for UNCOVER-3 have been previously reported. 3, 4 Briefly, eligible patients were randomized at a 2:2:2:1 ratio to double-blind treatment groups receiving subcutaneous injections of 80 mg ixekizumab every 2 weeks or every 4 weeks following an initial dose of 160 mg of ixekizumab, 50 mg etanercept twice weekly, or placebo, respectively, during a 12-week induction dosing period (weeks 0 to 12). For patients initially randomized to placebo (but not etanercept), an initial dose of 160 mg of ixekizumab was administered at week 12. At week 12, patients entered the long-term extension (LTE) period, during which they received 80 mg ixekizumab every 4 weeks. During LTE, patient visits occurred every 4 weeks from weeks 12 to 60 and every 12 weeks from weeks 60 to 108. After week 60, patients could increase their dosage from 80 mg every 4 weeks to 80 mg every 2 weeks of ixekizumab until end-ofstudy at the investigator's discretion.
The trial protocol was approved by the institutional review board or ethics committee at each participating site. All eligible patients provided written informed consent before undergoing study-related procedures. UNCOVER-3 was registered on July 18, 2012, with the registration number of NCT01646177. The first patient was enrolled on August 11, 2012.
Endpoints and outcome assessment
Efficacy was measured as the percentage of patients achieving at least a 75%, 90%, or 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75/90/100), as well as the percentage of patients achieving a static Physician's Global Assessment (sPGA) score of (0 or 1) or (0). 5 Efficacy was also evaluated in patients who had either baseline scalp or fingernail involvement as the percentage achieving a score of 0 for the Psoriasis Scalp Severity Index (PSSI) 6 or the Nail Psoriasis Severity Index (NAPSI), 7 respectively. An additional efficacy measure for patients with nonpustular palmoplantar involvement at baseline was the percentage of patients achieving a 100% improvement in the Palmoplantar Psoriasis Area and Severity Index (PPASI 100). 8 Safety was assessed through monitoring of adverse events (AEs), laboratory data, immunogenicity, electrocardiograms, and vital signs collected and reported by study investigators at regular intervals during patient visits. Selected AEs of special interest included neutropenia, infections, malignancies, Crohn disease, ulcerative colitis, and cerebrocardiovascular events. Cerebrocardiovascular events were adjudicated in a blinded manner by an independent committee of experts.
CAPSULE SUMMARY d
Ixekizumab has previously been shown to be an efficacious and well-tolerated treatment for moderate-to-severe plaque psoriasis through 60 weeks. Ixekizumab therapy is appropriate for long-term treatment of patients with plaque psoriasis.
Statistical analysis
For efficacy, all randomized patients were analyzed as intention to treat or according to the treatment to which they were assigned (regardless of compliance). Efficacy data were summarized by using the following 3 methods at each postbaseline visit through week 108: as-observed, multiple imputation (MI), 9 and a modified MI (mMI) approach using MI and nonresponder imputation (NRI) combined imputation (which has also been referred to as modified NRI in the literature). 10, 11 For as-observed case analyses, the analyses were done with patients only for whom observations were available and did not include any imputation for missing values. In the MI analyses, missing data were imputed to estimate what observations would have been if the patient had not discontinued. Specifically, MI is the partial imputation of nonmonotone missing data using Markov chain Monte Carlo method with the simple imputation model, followed by a sequential regression imputation with the baseline score. In some cases, missing data is the result of subjects discontinuing because of reasons related to safety or efficacy (reasons attributable to the study drug). Thus, mMI was used as a conservative analysis method to account for these causes of discontinuation. Subjects who discontinued because of AEs or lack of efficacy/relapse were considered nonresponders and were imputed as NRI. In all other cases of missing data for this analysis, the data were imputed using the above MI method.
Because patients could increase their dosage from 80 mg ixekizumab every 4 weeks to 80 mg ixekizumab every 2 weeks after week 60, summaries (as-observed, MI, mMI) were produced that included and excluded data from visits with dose increases to every 2 weeks long-term dosing.
Safety data were summarized by frequency of events occurring after week 12 during the LTE period with the LTE population, defined as patients who completed a 12-week induction dosing period and received $1 dose of study treatment during the LTE period.
RESULTS
Patient characteristics
In UNCOVER-3, a total of 1346 patients were randomized, and 1274 (94.7%) completed week-12 assessments and entered the LTE period; 1068 (79.3%) patients completed 108-week assessments. In total, 206 (16.2%) patients in the LTE population discontinued treatment. Overall, 38 (3.0%) patients discontinued treatment because of a lack of efficacy, and 82 (6.4%) discontinued because of AEs (including deaths). Baseline demographics and patient characteristics were similar among treatment regimens (Table I) .
Efficacy
The high response rates observed during earlier treatment periods 3, 4 persisted through 108 weeks of treatment. In patients receiving the recommended dose of 80 mg ixekizumab every 2 weeks during induction and every 4 weeks during LTE (N = 385), the respective as-observed, MI, and mMI 108-week response rates were 93.4%, 88.3%, and 83.6% for PASI 75; 79.7%, 73.5%, and 70.3% for PASI 90; 56.3%, 50.7%, and 48.9% for PASI 100; 82.6%, 78.3%, and 74.1% for sPGA (0,1); and 57.0%, 57.3%, and 53.0% for sPGA (0) (Figs 1 and 2). Response rates were similar for each treatment arm at 108 weeks.
Clearance rates of fingernail, scalp, and nonpustular palmoplantar psoriasis persisted through 108 weeks for patients with baseline involvement at each respective body site. The 108-week as-observed and mMI clearance rates of fingernail psoriasis (NAPSI score = 0) for patients receiving the recommended dosage of ixekizumab were 69.0% and 62.8%, respectively (Fig 3, A) . For scalp (PSSI = 0), the 108-week clearance rates for as-observed and mMI were 86.8% and 76.0%, respectively; for nonpustular palmoplantar psoriasis (PPASI 100), the 108-week clearance rates for as-observed and mMI were 89.7% and 77.9%, respectively (Fig 3, B) . Clearance rates of fingernail, scalp, and nonpustular palmoplantar psoriasis were similar between treatment regimens.
Following week sixty, 48 of 1274 (3.8%) patients increased ixekizumab dosage to 80 mg every 2 weeks at the investigator's decision. At the visit before dose escalation, 13 (27.1%) patients had an sPGA score of 3 (moderate disease), and the remaining 35 (72.9%) had an sPGA score of #2. In addition, at the visit before dose increase, 38 (79.2%) patients who increased dosage to ixekizumab every 2 weeks To determine response rates for patients who received the recommended dosing regimen throughout the duration of the study (ixekizumab every 2 weeks then ixekizumab every 4 weeks after week 12 without increasing dose frequency to ixekizumab every 2 weeks at week 60), response rates were further evaluated by excluding data from patient visits in which the dosage had been increased to ixekizumab every 2 weeks (Fig 4) . The respective as-observed, MI, and mMI response rates for patients receiving the recommended dosage were 94.1%, 88.2%, and 83.4% for PASI 75 and 83.9%, 78.1%, and 73.4% for sPGA (0,1). At week 108, the mean duration of exposure to the increased ixekizumab every 2 weeks dose frequency was 98.4 (standard deviation 638.7) days for the ixekizumab every 2 weeks and every 4 weeks treatment arms.
Safety
The frequency, severity, and distribution of treatment emergent adverse events (TEAEs) were similar between treatment arms. The most frequently observed TEAEs ($5%) during the LTE period included nasopharyngitis, upper respiratory tract infections, injection-site reactions, arthralgia, bronchitis, and headache (Table II) . Of 1077 (84.5%) TEAEs reported during the LTE period, 910 (85%) were either mild or moderate in severity.
Of the TEAEs of special interest occurring during LTE, Candida infections were among the most common, occurring at a rate of 3.8%. Grade 3 or 4 neutropenia was uncommon, occurring at a cumulative rate of 0.6%, with 1 grade 4 event occurring at week 108. The observed rate of treatment-emergent malignancies and cerebrocardiovascular events during LTE were 1.7% and 2.4%, respectively. Crohn disease and ulcerative colitis were rare, both occurring at a rate of 0.2% during the LTE period (Table II) .
Five deaths were reported during the LTE period of UNCOVER-3. Causes of death were hemorrhagic cerebral infarction, cardiorespiratory arrest, accidental death, senile dementia, and myocardial infarction. In all cases, deaths were judged as not related to ixekizumab treatment by the treating physician.
DISCUSSION
The current report provides evidence of persistent efficacy of ixekizumab over a 2-year period. The high response rates achieved during shorter ixekizumab treatment periods 3,4 were persistent were also high through 108 weeks of treatment. Discontinuation because of loss of efficacy during the LTE period was uncommon (3%), thus supporting persistent efficacy during long-term exposure to ixekizumab. Ixekizumab was well tolerated and no unexpected safety outcomes were reported in the LTE period of UNCOVER-3. The overall safety profile for ixekizumab during LTE was similar to previously reported shorter treatment periods. 4 The most common AE reported was nasopharyngitis, and most AEs were of mild or moderate severity. Discontinuation because of an AE remained low (6.4%). Five deaths were reported during the LTE period, and in all cases, the cause of death was judged by the treating investigators to be unrelated to ixekizumab exposure. Long-term efficacy response rates for the recommended dosing regimen excluding patient visits with increased dose frequency. PASI 75 (A) and sPGA (0,1) (B) response rates for each visit weeks 60-108 for the ixekizumab every 2 weeks (for weeks 0-12) and then ixekizumab every 4 weeks (for weeks 13-108) dosing regimen including (1 IXE Q2W) and excluding (e IXE Q2W) data from visits with patients receiving ixekizumab every 2 weeks. The as-observed sample size is provided for the 108-week visit. Error bars represent 95% confidence intervals. IXE, Ixekizumab; MI, multiple imputation; mMI, modified multiple imputation; PASI 75, 75% improvement from baseline in the Psoriasis Area and Severity Index; Q2W, every 2 weeks; sPGA (0,1), static Physician's Global Assessment score of 0 or 1.
A B rate at week 108 (%) n = 288 n = 349 n = 349 n = 78 n = 96 n = 96 response rate (%) Fig 3. Fingernail, scalp, and nonpustular palmoplantar psoriasis clearance rates at 108 weeks with recommended ixekizumab dosing regimen. A, NAPSI = 0 response rate at each postbaseline visit for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. Only fingernail psoriasis was assessed in UNCOVER-3. B, PSSI = 0 and PPASI 100 response rate at 108 weeks for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. Response rates are determined for patients with baseline fingernail, scalp, or nonpustular palmoplantar psoriasis. The as-observed sample size for each measure is provided for the 108-week visit. Error bars represent 95% confidence intervals. MI, Multiple imputation, mMI, modified nonresponder imputation; NAPSI = 0, Nail Psoriasis Severity Index score of 0; PPASI 100, 100% improvement from baseline in the Palmoplantar Psoriasis Area and Severity Index; PSSI = 0, Psoriasis Scalp Severity Index score of 0.
There are several AEs of interest for therapeutic agents targeting IL-17A. IL-17A plays a key role in regulating both inflammation and neutrophil homeostasis.
12,13 IL-17Aemediated immunity is also a key factor in protecting against infection by Candida spp.
14 Aberrant IL-17A signaling has also been hypothesized to be linked to inflammatory bowel diseases, cardiovascular disease, and tumorigenesis. 15, 16 Furthermore, the incidence of inflammatory bowel disease, cardiovascular disease, and malignancies are increased in patients with psoriasis, making these events of special interest. [17] [18] [19] [20] [21] In the LTE population of UNCOVER-3,
Candida spp infections were among the most commonly reported AEs of special interest but were still infrequent, occurring in \5% of patients. The rates of grade 3 or 4 neutropenia were rare (\1%) during long-term ixekizumab treatment.
Crohn disease and ulcerative colitis were also both rare, reported in 0.2% of patients during LTE. Reports of treatment-emergent cerebrocardiovascular events and malignancies were reported in \3% and \2% of the LTE population, respectively. The UNCOVER-3 study included sites across 10 countries and had a geographically diverse patient population. Thus, a strength of this study is that it 
Placebo was administered with 2 injections on week 0 then every 2 weeks. Etanercept (50 mg) was administered twice weekly. Ixekizumab (80 mg) was administered at 2 frequencies: Q2W and Q4W. ETN, Etanercept; IXE, ixekizumab; Q2W, every 2 weeks; Q4W, every 4 weeks. *Adverse events include events that first occurred or worsened during the long-term extension treatment period. Adverse events reported here are cumulative and includes events from the long-term extension population that occurred during the treatment period before the 108-week database lock. y For patients with [1 occurrence of the same event, severity was categorized on the basis of the event of the highest severity. z Common adverse events included any adverse event occurring at a rate of [5% in the total long-term extension population.
x Cerebrocardiovascular events were only included if they were confirmed by adjudication. jj Candida infections include MedDRA high-level terms and MedDRA preferred terms for events likely representing Candida infections.
Specific terms include vulvovaginal candidiasis, vulvovaginal mycotic infection, oral candidiasis, candida infection, skin candida, oral fungal infection, balanitis candida, nail candida, and genital candidiasis. { Treatment-emergent neutropenia was reported for patients who experienced a worsening from baseline neutrophil counts at any time during the long-term extension period. Percentages were calculated based on the number of patients in each comparison group with a baseline and $1 postbaseline neutrophil measurement: placebo and IXE Q4W (N = 182), ETN and IXE Q4W (N = 368), IXE Q4W and IXE Q4W (N = 357), IXE Q2W and Q4W (N = 362), and total (N = 1269). Neutropenia grades are defined as follows: grade 1, \2000/mm 3 and $1500/mm 3 ; grade 2, \1500/mm 3 and $1000/mm 3 ; grade 3, \1000/mm 3 and $500/mm 3 ; and grade 4, \500/mm 3 .
includes a large randomized patient population that is generally representative of patients with moderate-to-severe plaque psoriasis. A study limitation, however, is that the LTE period is openlabel, thus lacking long-term head-to-head efficacy and safety comparisons to placebo or etanercept, which were included during the first 12 weeks of UNCOVER-3. Overall, the results presented demonstrate that ixekizumab is well tolerated and provides a persistent and long-term clinical response through 108 weeks of treatment in patients with moderate-to-severe plaque psoriasis. A more comprehensive analysis of integrated long-term safety data will be provided in later publications.
